Une traduction en français de ce résumé figure à la fin de l'article. Al final del artículo se facilita una traducción al español. ‫اﻟﺘﺮﺟﻤﺔ‬ ‫اﻟﻌﺮﺑﻴﺔ‬ ‫ﻟەذە‬ ‫اﻟﺨﻼﺻﺔ‬ ‫ﻓﻲ‬ ‫ﻧەاﻳﺔ‬ ‫اﻟﻨﺺ‬ ‫اﻟﻜﺎﻣﻞ‬ ‫ﻟەذە‬ ‫.اﻟﻤﻘﺎﻟﺔ‬
Introduction
Much has been written about the impact of intellectual property (IP) provisions on access to medicines in the developing world. [1] [2] [3] [4] [5] [6] [7] In recent years, this discussion has often centred on the impact of free trade agreements with the United States of America (USA) that contain elevated protection for pharmaceutical IP. Typically, views are deeply polarized: some decry the free trade agreements' provisions as inevitably disastrous for public health [8] [9] [10] [11] [12] [13] while others argue that IP protection does not constitute a significant obstacle to access to medicines. [14] [15] [16] [17] [18] As countries contemplate ratification, the lack of available studies forecasting the impact of such regulations (or the lack of agreement on which studies to trust) has further hampered the discussion. Assessing DR-CAFTA's current impact on access to medicines is a complex undertaking, beyond the scope of the present study. As a first step towards that end, however, we seek to determine which legislative changes have been implemented in each Central American country as a result of its adherence to DR-CAFTA. This study draws on analysis of the text of international agreements (DR-CAFTA and the TRIPS Agreement), analysis of national legislation in Central American countries and in the Dominican Republic, and interviews with public health and trade officials and representatives of civil society in Costa Rica, El Salvador and Guatemala.
Our research documents a dramatic tightening of Central American IP regulation in the wake of DR-CAFTA. At the same time, however, our findings suggest that the relationship between the text of international agreements (both DR-CAFTA and TRIPS) and the "public health sensitivity" of legislation 19, 20 is not as direct as many assume. First, in some cases restrictive reforms were adopted prior to the ratification of the agreements themselves. Second, in many cases countries have implemented more restrictive standards than those required in these agreements. Third, in some cases, the DR-CAFTA ratification process actually led to the implementation of legislation sensitive to public health. Our purpose is not to argue that trade agreements like DR-CAFTA are not important in determining IP policy, but rather to emphasize continuities between these agreements and broader trends in IP policymaking, which are often eclipsed by the intense focus on trade agreements and their ratification. We explain the reasoning for these arguments here, using the examples of new IP provisions imported by DR-CAFTA to Central America, and conclude with a discussion of their broader implications. but regulations had yet to be devised for their implementation.
IP in Central America
As Table 1 shows, both the content of legislation and the dates of its passage vary widely from country to country. In many cases -that of Guatemala in particular -IP restrictive legislation was passed before the ratification of DR-CAFTA, and the political controversies associated with the ratification process led to the eventual repeal of such legislation in favour of alternatives more sensitive to public health. 27, 28 Guatemala is not the only country in which this occurred.
In Table 2 , we analyse the legislation in force in Central America both before and after the passage of DR-CAFTA. We note the presence of "opportunities" and "threats"
to public health, using a framework for analysing the public health impact of IP developed by Chaves and Oliveira.
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"Opportunities" include mechanisms that harmonize IP protection with public health objectives, such as specifications to limit patents, exceptions to patent rights that offer opportunities for timely generic drug production, and provisions for parallel importation, compulsory licensing and government use.
"Threats" include patent term extension, mandated linkage between health safety requirements and patent protection, and test data exclusivity that delay the availability of generic drugs. More detailed analysis of these opportunities and threats can be found elsewhere.
5,29-32
A detailed discussion of all the specific provisions detailed above would occupy more space than this paper permits. To illustrate the broad trend, therefore, we discuss has called "the global intellectual property ratchet," whereby the USA and
European Union have used a combination of multilateral and bilateral strategies to push in concerted fashion for ever higher IP standards. As Tables 3 and 4 show, in both of these provisions, TRIPS imposed a standard which was subsequently superseded by DR-CAFTA, which many Central American countries chose to interpret in ways that raise the bar even higher for IP protection. 
Discussion
In the DR-CAFTA region, while all countries are bound by the same international laws, specific provisions in national law as well as varying levels of political will and resources to implement such laws lead to dramatically different consequences among countries.
This complicates the task of assessing the impact of international trends, for most often the aspects which most decisively determine the extent of their application are found in national laws, regulations and practices. These forms of IP lawmaking typically fly "below the radar screen" for those engaged in debates about trade and access to medicines, but they are a critically important site for attention in determining the impact of the current trade regime on health.
Our analysis of the implementation of the transnational IP norms yields some surprising findings. First, sometimes IP legislation was passed before ratification of the agreement (Table 1) . Second, IP legislation often imposes a stricter standard than that required by the agreement itself (Table 2) . And third, in some cases, specific aspects of national legislation became more public health sensitive over the course of treaty implementation ( Table 2, Table 3 and Table 4 ).
How do we make sense of these findings? First, the passage of trade agreements with strong IP provisions is just one of the most visible of many related tactics that, taken together, constitute a sustained campaign. While debates over ratification capture the most attention, it is not only through formal ratification that these processes advance the Finally, although the openings for democratic participation are limited, the ratification process does afford some positive opportunities for political mobilization around the right to health. In Central America, the passage of DR-CAFTA created more controversy than the passage of TRIPS-compliant legislation somewhat earlier; in some limited cases, the discussion prompted by DR-CAFTA led to re-examination of previous laws that had been passed with little debate. The best example of this is Guatemala, where civil society's engagement with the ratification process led to the overturning of more restrictive IP legislation in favour of more public health sensitive alternatives, when they reduced the test data protection period from 15 to 5 years (Table 1) . Although focusing on the ratification process exclusively may obscure the multifaceted ways in which IP policy is determined, public health advocates should not lose sight of the opportunities that it affords.
Conclusion
During the process of trade agreement ratification, attention is often focused on the implications of IP for public health. This public scrutiny can have positive effects. At the same time, our findings show that more sustained attention to these issues is needed: not only did most Central American countries pass laws mandating the bulk of DR-CAFTA's IP provisions well before the signing of the agreement, but they continued to implement these provisions much later than the agreement's ratification. The window of opportunity for public health intervention in policy discussions therefore can not afford to be limited to the period immediately surrounding treaty ratification.
Similarly, the topics under scrutiny must extend beyond the text of these agreements alone. National implementing legislation varies greatly from country to country, and is affected by conditions external to the negotiations of the agreement. Both before and following DR-CAFTA's ratification, the Central American countries responded to pressure from such forces by tightening their IP norms. This suggests the importance of understanding trade agreements as part of a broader, longer-term strategy on the part of the transnational pharmaceutical industry and its allies. Our purpose is not to suggest that the treaty's impact is negligible, but rather that these changes must be understood in broader perspective as, overall, contributing to a tightening of IP norms in the region, the impact of which has yet to be fully understood.
Further study is required to determine the extent to which these laws, once widely implemented, limit access to medicines in Central America. Also, while the country-bycountry analysis undertaken here is absolutely necessary to understand the impacts of regional free trade agreements on the ground, given the global market in medicines, national analyses alone provide insufficient measures of the impacts of these norms. In
Central America, for example, many generic medicines are imported from countries outside the region, including Colombia and India. In reaction to the rising IP demands of American free trade agreements (in the case of Colombia), direct challenges from American pharmaceutical companies (as in India), and political pressures from the American and other governments, these countries tighten their national IP legislation, which inevitably impacts the drugs they export. In Central America and other areas without major drug production capacity, the availability of generic medications is not only influenced by local legislation but by decisions made in far-away courts and congresses, which may cut off the flow of affordable medications at its source. As the public health community strives to better understand the impact of IP norms on access to affordable drugs, it is imperative that we undertake research that is both rooted in Publication: Bulletin of the World Health Organization; Type: Policy and Practice Article DOI: 10.2471/BLT.08.056010
Page 9 of 15 national particularities and sensitive to the crosscutting effects of changes at the international and transnational level.
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